ARTICLE | Finance
Record-setting series A for Denmark’s Adcendo clears path to POC
At €51M, ADC play’s A round is largest ever for a Danish biotech
April 30, 2021 12:08 AM UTC
A €51 million ($62 million) series A round by Adcendo lands the Danish ADC company a spot among European biotech’s 15 largest series A rounds and sets the company up to carry its lead program through clinical POC testing for cancer.
Novo Seeds and Ysios Capital led the round, the largest ever for a Danish biotech, according to BioCentury’s BCIQ database, which has been tracking biotech financings since 1994. U.K.-based Immunocore Holdings Ltd. (NASDAQ:IMCR) holds the No. 1 spot for all of Europe with a $320 million series A in 2015...